期刊
PSYCHONEUROENDOCRINOLOGY
卷 26, 期 6, 页码 551-564出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0306-4530(01)00010-5
关键词
premenstrual dysphoric disorder; GnRH-agonist; serotonin; paroxetine; lysergic acid diethylamide; platelets
Changes in serotonergic parameters have been reported in psychiatric conditions such as depression but also in the premenstrual dysphoric disorder (PMDD). In addition, hormonal effects on serotonergic activity have been established. In the present;study, binding of [H-3]paroxetine to platelet serotonin uptake sites: and binding of [H-3]lysergic acid diethylamide ([H-3]LSD) to platelet serotonin (5-HT)(2A) receptors were studied in patients with PMDD treated with a low dose of a gonadotropin releasing hormone (GnRH) agonist (buserelin) or placebo and compared to controls. The PMDD patients were relieved of premenstrual symptoms like depression and irritability during buserelin treatment. The number of [H-3]paroxetine binding sites (B-max) were significantly higher in the follicular phase in untreated PMDD patients compared to controls. When treated with buserelin the difference disappeared. No differences in [ H-3]LSD binding between the three groups were shown. The present study demonstrated altered platelet [3H]paroxetine binding characteristics in women with PMDD compared to controls. Furthermore, [H-3]paroxetine binding was affected by PMDD treatment with a low dose of buserelin. The results are consistent with the hypothesis that changes in serotonergic transmission could be a trait in the premenstrual dysphoric disorder. (C) 2001 Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据